Theralase Technologies Inc. V.TLT

RE:Brain cancer

[Gustoes]

kungsuki wrote: Interesting how the N.R. also mentions "brain cancer" along with bladder.  

Indeed.

"The lead PDC has been identified to be TLD-1433, a ruthenium-based PDC that has demonstrated a high therapeutic ratio, which has the highest overall performance in the green and red laser light spectrums for multiple cancer cell lines, including glioma (primary brain tumours that originate from the supportive cells of the brain) and bladder cancer. "

A glioma is a type of tumor that starts in the brain or spine. It is called a glioma because it arises from glial cells. The most common site of gliomas is the brain.

Glioma is an umbrella term used to describe the different types of gliomas: astrocytoma, oligodendroglioma, and glioblastoma.

Glioblastomas (GBM) are tumors that arise from astrocytes—the star-shaped cells that make up the “glue-like,” or supportive tissue of the brain

So we'll take a look at glioblastoma

Therapeutic options for glioblastoma multiforme (GBM) are limited and have not changed for nearly a decade. Few drugs are in late-stage development for GBM and in recent years numerous drugs have disappointed in Phase III studies; current treatment for newly diagnosed GBM is still dominated by radiotherapy and temozolomide (Merck & Co.’s Temodar/Temodal, generics). The future use of bevacizumab (Roche/Genentech/Chugai’s Avastin) in the United States and Europe is shrouded in uncertainty following the announcement of equivocal data of this agent in Phase III studies. Two therapeutic vaccines in Phase III development hold promise of prolonging overall survival (OS); however, only select newly diagnosed GBM patients will likely benefit from these therapies.

Merck might be interested in ensuring they maintain this market. Since they'll be making TLD1433 (via Sigma Aldrich) maybe they'll take a look. :)